<DOC>
	<DOCNO>NCT00000976</DOCNO>
	<brief_summary>To determine safety profile recombinant human CD4-immunoglobulin G ( CD4-IgG ) zidovudine ( AZT ) combination therapy patient AIDS AIDS-related complex ( ARC ) ; ass pharmacokinetic ( blood level ) property CD4-IgG combination AZT ; obtain preliminary indication antiviral immunologic effect CD4-IgG combination AZT patient AIDS ARC . Treatment AIDS direct toward underlie retroviral infection well toward specific opportunistic infection malignancy associate syndrome . The extensively study drug reverse transcriptase inhibitor AZT nucleoside analogs , include didanosine ( ddI ) dideoxycytidine ( ddC ) . The extensive clinical experience achieve AZT . These clinical trial indicate decreased incidence opportunistic infection increase survival patient AIDS . However , AZT treatment associate dose-limiting toxicity . Additionally , identification resistance AZT increase need test effectiveness AZT combination drug . CD4-IgG capable binding HIV envelope protein ( gp120 ) inhibit HIV infectivity test tube study . Potential therapeutic benefit patient HIV infection may derive CD4-IgG .</brief_summary>
	<brief_title>A Phase I Study Safety Pharmacokinetics Recombinant Human CD4-Immunoglobulin G ( rCD4-IgG ) Administered Intravenous Bolus Injection Combination With Oral Zidovudine Patients With AIDS AIDS-Related Complex</brief_title>
	<detailed_description>Treatment AIDS direct toward underlie retroviral infection well toward specific opportunistic infection malignancy associate syndrome . The extensively study drug reverse transcriptase inhibitor AZT nucleoside analogs , include didanosine ( ddI ) dideoxycytidine ( ddC ) . The extensive clinical experience achieve AZT . These clinical trial indicate decreased incidence opportunistic infection increase survival patient AIDS . However , AZT treatment associate dose-limiting toxicity . Additionally , identification resistance AZT increase need test effectiveness AZT combination drug . CD4-IgG capable binding HIV envelope protein ( gp120 ) inhibit HIV infectivity test tube study . Potential therapeutic benefit patient HIV infection may derive CD4-IgG . AMENDED : Previously , rCD4-IgG administer mcg/kg basis . Subjects receive rCD4-IgG fix dose . Changes maintenance schedule make accommodate new dosage . Original design : This study divide two part : A pharmacokinetic evaluation , safety evaluation . The pharmacokinetic evaluation do select patient . For safety evaluation patient receive rCD4-IgG fix dose level twice weekly intravenous bolus injection ( 1 minute ) 12 week . Zidovudine ( AZT ) administer orally 3 time daily one two dose level . Eight subject , least 4 p24 level great 75 pg/m , enter dose level CD4-IgG begin dose level 1 . If 3 patient dose level experience grade 3 4 toxicity patient add high dose level . Pharmacokinetics CD4-IgG alone combination AZT evaluate patient dose level 2 . Patients receive one IV bolus CD4-IgG day 1 sample draw begin 15-30 minute prior CD4-IgG injection . There 8 day washout period . Beginning day 9 continue day 24 , patient receive AZT daily . CD4-IgG administered IV bolus day 16 . Samples draw begin 15-30 minute prior injection CD4-IgG . The pharmacokinetic evaluation terminate 8 day second CD4-IgG injection ( day 24 ) . Extended treatment make available patient discretion Principal Investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical acyclovir . Patients must follow : HIV seropositivity . Life expectancy least 3 month . No white red blood cell cast urine . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Serious active opportunistic infection malignancy Kaposi 's sarcoma . Kaposi 's sarcoma require therapy , tumorassociated edema , visceral disease . Concurrent Medication : Excluded : Intravenous acyclovir Herpes . Interferon . Systemic corticosteroid . Nonsteroidal antiinflammatory agent . Intravenous acyclovir . Other known immunomodulatory agent . Dideoxycytosine ( ddC ) , didanosine ( ddI ) . Other nucleoside analog specifically allow . Other experimental therapy . Patients follow exclude : Serious active opportunistic infection malignancy Kaposi 's sarcoma . More 120 day ( total ) prior zidovudine ( AZT ) therapy . Currently receive intravenous acyclovir Herpes . Prior Medication : Excluded : &gt; 120 day total prior zidovudine ( AZT ) therapy . Excluded within 3 week study entry : Immunomodulatory agent . Other experimental therapy . Prior Treatment : Excluded within past 3 month : Transfusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1994</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>IgG</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Carrier Proteins</keyword>
</DOC>